Found: 240
Select item for more details and to access through your institution.
Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The inhibin-βC subunit is down-regulated, while inhibin-βE is up-regulated by interferon-β1a in Ishikawa carcinoma cell line.
- Published in:
- Archives of Gynecology & Obstetrics, 2013, v. 288, n. 4, p. 883, doi. 10.1007/s00404-013-2848-2
- By:
- Publication type:
- Article
Inhibition of Microglial Activation by Amitriptyline and Doxepin in Interferon-β Pre-Treated Astrocyte–Microglia Co-Culture Model of Inflammation †.
- Published in:
- Brain Sciences (2076-3425), 2023, v. 13, n. 3, p. 493, doi. 10.3390/brainsci13030493
- By:
- Publication type:
- Article
First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Papain-like protease of SARSCoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitinationindependent manner.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.947272
- By:
- Publication type:
- Article
Should anti-CD20 be used as an immune reconstitution therapy?
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 2, p. 308, doi. 10.1177/13524585221109386
- By:
- Publication type:
- Article
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1927, doi. 10.1177/13524585221097561
- By:
- Publication type:
- Article
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 4, p. 573, doi. 10.1177/13524585211032348
- By:
- Publication type:
- Article
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 13, p. 2001, doi. 10.1177/13524585211047977
- By:
- Publication type:
- Article
Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 2, p. 233, doi. 10.1177/1352458517719153
- By:
- Publication type:
- Article
Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 2, p. 231, doi. 10.1177/1352458517708465
- By:
- Publication type:
- Article
Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon-beta 1a: case report.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
- Published in:
- International Journal of Dermatology, 2015, v. 54, n. 4, p. 456, doi. 10.1111/j.1365-4632.2012.05840.x
- By:
- Publication type:
- Article
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
- Published in:
- 2018
- By:
- Publication type:
- journal article
EVASEP: A Noninterventional Study Describing the Perception of Neurologists, Patients, and Caregivers on Caregivers’ Role in the Support of Patients Suffering from Multiple Sclerosis Treated with Subcutaneous Interferon Beta 1a.
- Published in:
- Multiple Sclerosis International, 2016, p. 1, doi. 10.1155/2016/4986073
- By:
- Publication type:
- Article
Evolution of the RebiSmart<sup>®</sup> Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis.
- Published in:
- Patient Preference & Adherence, 2023, v. 17, p. 1923, doi. 10.2147/PPA.S414151
- By:
- Publication type:
- Article
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
- Published in:
- Patient Preference & Adherence, 2018, v. 12, p. 1289, doi. 10.2147/PPA.S157317
- By:
- Publication type:
- Article
Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart<sup>®</sup> injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis.
- Published in:
- Patient Preference & Adherence, 2017, v. 11, p. 1189, doi. 10.2147/PPA.S130985
- By:
- Publication type:
- Article
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis.
- Published in:
- Patient Preference & Adherence, 2017, p. 415, doi. 10.2147/PPA.S127508
- By:
- Publication type:
- Article
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.
- Published in:
- Patient Preference & Adherence, 2014, v. 8, p. 1123, doi. 10.2147/PPA.S68698
- By:
- Publication type:
- Article
Risk Factors of Death in Mechanically Ventilated COVID-19 Patients: A Multi- Center Study From Iran.
- Published in:
- Acta Medica Iranica, 2023, v. 61, n. 7, p. 408
- By:
- Publication type:
- Article
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.
- Published in:
- Allergy, 2024, v. 79, n. 4, p. 924, doi. 10.1111/all.15949
- By:
- Publication type:
- Article
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α-Based Regimens.
- Published in:
- Clinical Pharmacology & Therapeutics, 2014, v. 95, n. 2, p. 141, doi. 10.1038/clpt.2013.203
- By:
- Publication type:
- Article
Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
- Published in:
- 2016
- By:
- Publication type:
- journal article
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
- Published in:
- BMC Medical Imaging, 2016, v. 16, p. 1, doi. 10.1186/s12880-016-0158-4
- By:
- Publication type:
- Article
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy.
- Published in:
- Medicinal Research Reviews, 2021, v. 41, n. 2, p. 1167, doi. 10.1002/med.21756
- By:
- Publication type:
- Article
Zingiber officinale Roscoe Rhizomes Attenuate Oxaliplatin-Induced Neuropathic Pain in Mice.
- Published in:
- Molecules, 2021, v. 26, n. 3, p. 548, doi. 10.3390/molecules26030548
- By:
- Publication type:
- Article
Severe deterioration of newly diagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α for concomitant longstanding multiple sclerosis.
- Published in:
- Modern Rheumatology, 2012, v. 22, n. 3, p. 474, doi. 10.3109/s10165-011-0529-1
- By:
- Publication type:
- Article
The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.
- Published in:
- 2016
- By:
- Publication type:
- journal article
OP130 Economic Evaluation Of High-Cost Drugs For Relapsing-Remitting Multiple Sclerosis In Thailand.
- Published in:
- International Journal of Technology Assessment in Health Care, 2021, v. 37, n. S1, p. 2, doi. 10.1017/S0266462321000702
- By:
- Publication type:
- Article
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.
- Published in:
- BMC Pharmacology & Toxicology, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s40360-015-0025-x
- By:
- Publication type:
- Article
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 13, p. 1736, doi. 10.1177/1352458516683266
- By:
- Publication type:
- Article
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 10, p. 1367, doi. 10.1177/1352458516677589
- By:
- Publication type:
- Article
The impact of drugs for multiple sclerosis on sleep.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 1, p. 5, doi. 10.1177/1352458516664034
- By:
- Publication type:
- Article
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2016, v. 22, n. 12, p. 1626, doi. 10.1177/1352458516641774
- By:
- Publication type:
- Article
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
- Published in:
- Multiple Sclerosis Journal, 2016, v. 22, n. 11, p. 1495, doi. 10.1177/1352458515618020
- By:
- Publication type:
- Article
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis.
- Published in:
- Multiple Sclerosis Journal, 2016, v. 22, n. 5, p. 668, doi. 10.1177/1352458515599072
- By:
- Publication type:
- Article
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 9, p. 1159, doi. 10.1177/1352458514559865
- By:
- Publication type:
- Article
Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 7, p. 894, doi. 10.1177/1352458514555786
- By:
- Publication type:
- Article
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in ...
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 13, p. 1704, doi. 10.1177/1352458514532317
- By:
- Publication type:
- Article
Interferon beta treatment of multiple sclerosis increases serum interleukin-7.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 13, p. 1727, doi. 10.1177/1352458514532700
- By:
- Publication type:
- Article
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Thrombotic thrombocytopenic purpura-haemolytic uremic syndrome in relapsing–remitting multiple sclerosis patients on high-dose interferon beta.
- Published in:
- 2014
- By:
- Publication type:
- Opinion
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 9, p. 1265, doi. 10.1177/1352458514521311
- By:
- Publication type:
- Article
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 5, p. 566, doi. 10.1177/1352458513502399
- By:
- Publication type:
- Article
Treatment of progressive MS.
- Published in:
- 2013
- Publication type:
- Abstract